Morningstar's Christine Benz discusses reducing the drag of taxes on a portfolio and shares some of her favorite mutual funds.
The best-performing sectors thus far in 2016--utilities, consumer staples, energy, and basic materials--all look overvalued to our analysts.
The Chinese search giant's run-in with regulators doesn't have a major impact on our view of the firm's valuation, but the incident emphasizes regulatory and stewardship risks.
Continued worries about Anthem’s lawsuit have created a buying opportunity in the pharmacy benefit manager, says Morningstar’s Matt Coffina.
The online travel agency has hit a few recent bumps, but the firm's long-term competitive advantages are intact and shares look attractive, says Morningstar’s Matt Coffina.
Harold Evensky's concept for portfolio allocation can help bring retirees peace of mind and avoid poorly timed sales, says Morningstar's director of personal finance.
Morningstar’s Matt Coffina shares his takeaways from the Berkshire meeting, including how the reinsurance business is better positioned to withstand negative rates than its peers.
Oracle's moat will be put to the test, but the firm has a good chance of retaining customers, says Morningstar's Matt Coffina.
A leader in healthcare information technology, Cerner has a naturally scalable business with good competitive advantages, says Morningstar's Matt Coffina.
Our other consumer staples picks are trading at more reasonable valuations than Coke, with fewer secular headwinds, says Morningstar's Matt Coffina.
In open letter to the Baidu CEO and Board, shareholder and StockInvestor Editor Matt Coffina spells out his objections to a proposed sale of video platform iQiyi.
Utility ITC Holdings is looking for a buyer. Here's what investors should consider when a company they own is up for sale.
Major pharmacy benefit managers and pharma stocks with innovative pipelines should see the most upside, while companies that rely heavily on price increases for growth will likely suffer, says Morningstar's Matt Coffina.
Alphabet, Visa, and Novo Nordisk outperformed, while energy and basic materials were a drag on returns, says Morningstar's Matt Coffina.
We're unenthusiastic about the valuation of the broader market, but opportunities can be found in a few out-of-favor sectors.
With their vast libraries of content and popular channels, Disney, Twenty-First Century Fox, and Time Warner are well positioned to withstand consumers' shift away from traditional viewing habits, says Morningstar's Matt Coffina.
StockInvestor editor Matt Coffina recently sold out of Charles Schwab and trimmed Visa and Lowe's as current prices offer little margin of safety for the wide-moat names.
Stock-pickers using reasonable interest-rate assumptions can find opportunity among beaten-down utilities and REITs, says Morningstar's Matt Coffina.
Out-of-favor media and railroad names replaced several energy equities in Morningstar's index of most-undervalued wide-moat stocks, says Morningstar's Matt Coffina.
A major beer merger, cautious investors in China, and promising data on a new diabetes drug are among the factors driving ratings changes at quarter-end, says Morningstar's Matt Coffina.
We favor bottom-up stock analysis to find pockets of value amid a fairly valued market.
Time Warner is well positioned in the changing media landscape, says Morningstar's Matt Coffina.
Interest-rate fears bring utility and real estate valuations in line, but the broader market still looks fully valued.
Coal headwinds should only be temporary for wide-moat Union Pacific, which gives it an advantage over other rail companies, says Morningstar's Matt Coffina.
We recently upgraded a few banks and enterprise software firms to wide moat status, and raised our fair value estimates on health-care REITs.
First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.
Companies operating in constructive regulatory environments as well as those with cleaner and more efficient energy production will be better positioned, says Morningstar's Charles Fishman.
In our mid-meeting update, Morningstar's Matt Coffina discusses Buffett's view of stock valuations, cost-cutting, and more.
Pharmacy benefit managers aren't household names, but recent consolidation in the industry is proving out the power of scale for these firms, says Morningstar's Matt Coffina.
Active management isn't for everyone, but engaged and disciplined stock investors with long time horizons can achieve good results, says Morningstar's Matt Coffina.
We've adjusted our cost of capital and energy price assumptions, but we see little margin of safety and few opportunities in current stock prices.
ITC boasts much higher returns on capital and significantly lower risk than other utilities thanks to its friendlier regulatory situation, says Morningstar's Matt Coffina.
After lowering our forecast for oil and gas prices, fair values across the energy sector have generally dropped, but some E&P and midstream names are reasonably valued, says Morningstar's Matt Coffina.
Hear about Morningstar's latest take on energy stocks, the cost of equity, and real estate portals.
Though both are preferable to accumulating cash, paying dividends is a better method for preserving shareholder value, says Morningstar's Matt Coffina.
The robust earnings growth of recent years is unsustainable and will probably slow to 4% to 6% over the long run, says Morningstar's Matt Coffina.
This narrow-moat online travel agency should expand much faster than its competitors and currently looks attractively priced, even given the headwinds, says Morningstar's Matt Coffina.
Starting from current valuations, stocks simply aren't capable of delivering double-digit annualized total returns, says Morningstar's Matt Coffina.
Increased regulation could advantage high-tech disrupters and firms with economies of scale, says Morningstar's Jim Sinegal.
A likely slowdown in Chinese real estate will mean weaker demand for commodities such as iron ore and copper, but a few firms with sustainable low-cost positions should weather the storm.
Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.
Adventurous investors may find opportunities in out-of-favor energy and basic materials stocks, but the valuation of the overall market still leaves little margin for error.
Focused on sustainable competitive advantages and sensitive to valuation, Morningstar StockInvestor's Matt Coffina sees potential in a handful of Internet stocks today.
The sharp decline in oil prices reinforces the importance of purchasing stocks at a reasonable margin of safety, says Morningstar's Matt Coffina.
After his recent sale of Energy Transfer Equity, StockInvestor editor Matt Coffina says investors should consider more conservative MLPs whose current valuations are less dependent on future growth.
Morningstar strategist Matt Coffina discusses how he views interest rate, geopolitical, regulatory, currency, and valuation risk when managing the StockInvestor portfolios.
From moats to fair value to stewardship, we explain the key pillars of our approach to equities.
Forget about minimizing risk. Instead, make sure that you are adequately compensated for the risks you're taking on, says Morningstar's Matt Coffina.
Investors have started to pay attention to risk again, but market valuations overall don't offer much margin of safety, says Morningstar's Matt Coffina.
Moaty Accenture and Cognizant are well-positioned to meet growing demand for end-to-end services and global delivery capabilities.